Acadia misses estimates but reaffirms 2026 outlook and pivotal ADP catalyst

 

Acadia Q1 2026 revenue $268M (+11% YoY), EPS $0.02 (-82% YoY), misses estimates but reaffirms 2026 outlook and pivotal ADP catalyst

• Q1 revenue $268M, +11% YoY adjusted; both DAYBUE and NUPLAZID grew solidly.
• DAYBUE sales $101M, +20% YoY, boosted by strong initial DAYBUE STIX uptake.
• NUPLAZID sales $167M, +6% YoY; 8% demand, 11% referral growth despite refill delays.
• 2026 revenue guidance $1.22–$1.28B and brand-level sales and expense guidance reaffirmed; back-half weighted.
• Remlifanserin Phase II in Alzheimer's psychosis on track for August–October 2026 readout.
• Trofinetide Japan Phase III enrollment ahead of plan; top-line data expected September–November 2026.
• Cash balance $851M, positive operating cash flow, supporting internal pipeline and business development optionality.
• SG&A up to $171M from $126M, reflecting sales force expansion and marketing spend.
• European trofinetide reexamination ongoing; decision expected by late June, potential EU Rett opportunity.
• R&D head retiring year-end; remains through key remlifanserin milestones, but succession introduces transition risk.
• Main concern: High-impact remlifanserin Alzheimer's psychosis data and European trofinetide decision could materially alter outlook.
• Strong quarter, driven by robust DAYBUE growth, stable NUPLAZID demand, and reaffirmed 2026 guidance.

https://finviz.com/quote?t=ACAD&p=d